论文部分内容阅读
目的研究雷替曲塞化疗联合放疗局部晚期直肠癌的疗效。方法 83例局部晚期直肠癌患者,随机分为组A(41例)和组B(42例)。组A采取5-氟尿嘧啶化疗+放疗;组B采取雷替曲塞化疗+放疗。两组放疗方案一致。观察控制率和毒副反应发生率。结果 1组B相比于组A控制率更高(P<0.05);2组B相比于组A毒副反应发生率更低(P<0.05)。结论雷替曲塞化疗联合放疗局部晚期直肠癌的疗效确切,可有效改善患者预后,且毒副反应可耐受,值得临床推广。
Objective To study the efficacy of raltitrexed combined with radiotherapy for locally advanced rectal cancer. Methods 83 patients with locally advanced rectal cancer were randomly divided into group A (41 cases) and group B (42 cases). Group A to 5-fluorouracil chemotherapy + radiotherapy; group B to take raltitrexed chemotherapy + radiotherapy. The two groups were the same radiotherapy. Observe the control rate and the incidence of toxic reactions. Results Compared with group A, the control rate of group B was higher (P <0.05). The incidence of side effects of group B was lower than that of group A (P <0.05). Conclusion raltitrexed combined with radiotherapy for locally advanced rectal cancer is effective and can effectively improve the prognosis of patients with toxic and side effects, which is worthy of clinical promotion.